LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Hello fellow warriors! Another week, another batch of research. It’s a bit slower now, I suppose researchers need holidays too, but here we go.
Stay strong and fight on! And a Happy 4th of July to our US subscribers!

As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.​

Clinical Research

• Phase 1 Trial: 177Lu-PSMA-617 Plus Darolutamide in High-Risk Localized Prostate Cancer
  ​This new clinical trial investigates the combination of 177Lu-PSMA-617 (Pluvicto) and darolutamide specifically for patients with high-risk localized prostate cancer. The study explores intensifying treatment before surgery to attack the cancer while it is still potentially curable. By combining targeted radiation that hits PSMA-expressing cells with darolutamide’s ability to block androgen signaling, researchers hope to shrink tumors more deeply and reduce the likelihood of early recurrence.​
  ​
• Phase 1 Trial: RIPCORD PSMA PET–Guided Adaptive Radiotherapy
  ​The RIPCORD trial at UT Southwestern is testing whether PSMA PET imaging can be used during treatment to customize the amount of radiotherapy a patient receives. Focusing on men with poly-metastatic castration-sensitive prostate cancer, the study uses interim 68Ga-PSMA-11 PET scans to adapt stereotactic ablative radiotherapy (SABR) rather than treating every lesion identically from the start. This adaptive approach aims to concentrate radiation on biologically persistent disease while reducing unnecessary treatment for lesions that show a complete metabolic response.
  ​
• Phase 1 Trial: GRPR-Targeted Radioligand Therapy (177Lu-A9-0631 and 225Ac-A9-0642)
  ​This first-in-human multicenter trial is evaluating GRPR-targeted radiopharmaceuticals as a new precision oncology platform for solid tumors, including prostate cancer. The study explores two different therapeutic radionuclides: Lutetium-177 (a beta emitter, linked to A9-0631) and Actinium-225 (an alpha emitter, linked to A9-0642). Because the gastrin-releasing peptide receptor (GRPR) is overexpressed in various cancers, including prostate, this theranostic approach uses specialized imaging to identify expression and help select patients who may benefit from these targeted radiation strategies.
  ​
• Phase 2 Trial: ARTO Trial Final Results in Oligometastatic mCRPC
  ​Final results from the ARTO trial provide strong evidence that adding metastasis-directed SBRT to abiraterone significantly improves survival in patients with oligometastatic castration-resistant prostate cancer. After a median follow-up of 53 months, the median overall survival was not reached in the SBRT arm, compared to 50 months in the control group. These findings suggest that combining targeted radiation with systemic therapy offers a clinically meaningful survival advantage without a clear increase in serious toxicity.​

Preclinical Research & Reviews

• PARP Inhibition Combined with Targeted T-Cell Activation in mCRPC
  ​This novel strategy combines the PARP inhibitor olaparib with STAR0602, a bifunctional T-cell agonist, to overcome immune resistance in metastatic castration-resistant prostate cancer. While prostate tumors are often “immune-excluded,” this combination works by increasing tumor immunogenicity through DNA damage while simultaneously driving the expansion of specific T-cell subsets. Preclinical models have shown that this dual approach leads to significant tumor regression and a polyclonal immune response capable of recognizing multiple tumor antigens.
  ​
• GPS-ProMPT: Molecular Profiling for Identifying Aggressive Disease
  ​A retrospective analysis of the Oxford GPS-ProMPT study demonstrates that genomic profiling can identify which prostate cancers are truly aggressive, often independent of their clinical features. Using a 17-gene Genomic Prostate Score (GPS), researchers found they could consistently predict oncological outcomes across different management types, including active surveillance and surgery. Notably, the study identified a large group of patients with clinically high-risk features but low genomic scores who had excellent outcomes, suggesting many patients could potentially be managed with less aggressive treatment.

​

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max